Compounds > ge 68
Page last updated: 2024-12-07

ge 68

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GE 68: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133044
CHEMBL ID93812
SCHEMBL ID9738669
MeSH IDM0235384

Synonyms (11)

Synonym
CHEMBL93812
(+-)-3-(2-phenylethyl)-alpha-((propylamino)methyl)-2-benzofuranmethanol
3-(2-phenylethyl)-alpha-((propylamino)methyl)-2-benzofuranmethanol
2-benzofuranmethanol, 3-(2-phenylethyl)-alpha-((propylamino)methyl)-, (+-)-
158358-22-6
ge-68
ge 68
SCHEMBL9738669
DTXSID00935909
1-[3-(2-phenylethyl)-1-benzofuran-2-yl]-2-(propylamino)ethan-1-ol
1-[3-(2-phenylethyl)-1-benzofuran-2-yl]-2-(propylamino)ethanol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID43867The reversion potency of compound was measured against P-glycoprotein expressing CCRF-CEM cells and expressed as the ratio of ED50 in the absence and presence of daunomycin1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.
AID19431Partition coefficient (logP)1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance.
AID43400Effective dose against CCRF-CEM vcr 100 cells by using MTT assay1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance.
AID29120Calculated partition coefficient (clogP) (Molgen)2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivity.
AID44361In vitro multi drug resistance (MDR) reversal inhibitory activity against CCRF-CEM/VCR-1000 cell line2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivity.
AID43525The chemosensitizing effect was measured against P-glycoprotein expressing CCRF-CEM cells in the presence of 5 uM daunomycin1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.
AID43402Effective dose against CCRF-CEM vcr 100 cells by using rhodamine efflux studies.1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance.
AID29119Calculated partition coefficient (clogP) (HINT)2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Three-dimensional quantitative structure-activity relationship analysis of propafenone-type multidrug resistance modulators: influence of variable selection on test set predictivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.21 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index60.59 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		2.3920aromatic ether;
nitrile;
polyether;
tertiary amino compound
propafenone
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.		2.9140aromatic ketone;
secondary alcohol;
secondary amino compound		anti-arrhythmia drug
5-hydroxypropafenone
[no description available]		2.0110phenols
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		2.730
polysulfide rubber
[no description available]		2.6930
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0610